Last reviewed · How we verify
NCT07408661
Application of Artificial Intelligence and Iron Metabolism Markers in Predicting ICU Outcomes for Critically Ill Cancer Patients
trial in Cancer in 1,137 participants. Completed in 1 December 2025.
1 October 2024
Quick facts
| Lead sponsor | Tongji University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,137 |
| Start date | 1 January 2015 |
| Primary completion | 1 October 2024 |
| Estimated completion | 1 December 2025 |
Conditions studied
- Cancer — all drugs for Cancer →
Sponsor
Tongji University
Who can join
Adults 18 to 100, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aimed to develop a more accurate way to predict the 30-day survival of cancer patients admitted to the intensive care unit (ICU). The researchers focused on markers of iron metabolism, as imbalances in iron are common in cancer and severe illness. The study analyzed data from 1,137 critically ill cancer patients. Using artificial intelligence (AI), specifically a model called TabPFN, the study combined these iron markers with other routine clinical data (like blood cell counts and lactate levels) to create a new prediction tool.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07408661
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cancer
Currently open trials in the same condition.
- NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
- NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
- NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
- NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
- NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting
Other Tongji University trials
Trials by the same sponsor.
- NCT07361237 — A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor E · Phase 1 · recruiting
- NCT07208123 — Mechanistic Studies of Chronic COPD Using Single-Cell Sequencing and Single-Cell Spatial Transcriptomics · not yet recruiting
- NCT07047859 — Clinical Investigation of Sympathetic Nerve Width Measurement in Thoracoscopic Sympathectomy · not yet recruiting
- NCT07074704 — tACS to Improve Negative Symptoms & Cognition in Long-term Hospitalized Schizophrenia Patients. · NA · enrolling by invitation
- NCT06740188 — Trazodone on NREM Sleep Stage Ⅲ in Depressed Insomniac Co-morbid Patients · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07408661 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tongji University
- Last refreshed: 13 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07408661.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing